期刊文献+

妇科恶性肿瘤骨转移诊治的中国专家共识(2025年版) 被引量:1

Chinese expert consensus on the diagnosis and treatment of bone metastases in gynecological malignant tumors(2025 Edition)
暂未订购
导出
摘要 妇科恶性肿瘤骨转移虽较为少见,然而一旦出现,患者预后往往不佳。骨转移常伴随骨骼相关事件(SRE),严重影响患者的生存情况和生活质量。为提升妇科恶性肿瘤患者的生活质量、延长患者的生存期,骨转移的早发现、早诊断和早治疗至关重要。目前临床针对妇科恶性肿瘤骨转移的诊治方式各异,国内缺乏针对性的指南和专家共识。本共识制定小组以循证医学证据为基础,结合国内外文献、相关指南及专家意见,旨在为妇科恶性肿瘤骨转移的诊疗提供参考。 Bone metastasis in gynecological malignant tumors is relatively rare,but once it occurs,the prognosis of patients is often poor.Bone metastasis often accompanies skeletal-related event(SRE),which seriously affect the survival and quality of life of patients.Therefore,early detection,diagnosis,and treatment of bone metastasis are crucial for improving the quality of life and prolonging the survival of patients with gynecological malignant tumors.Currently,there are various diagnostic and therapeutic approaches for gynecological malignant tumors bone metastasis in clinical practice,and there is a lack of specific guidelines and expert consensus in China.The expert consensus drafting group,based on the evidence-based approach,combined domestic and foreign literatures,relevant guidelines,and expert opinions,aims to provide reference for the diagnosis and treatment of bone metastasis in gynecological malignant tumors.
作者 中国抗癌协会中西整合卵巢癌专业委员会 中国抗癌协会整合妇科肿瘤委员会 张颐 张师前 范江涛 邓雷 李芳梅 孔为民 薛凤霞 张岩 刘畅 赵喜娃 赵虎 Chinese and Western Integrated Ovarian Cancer Professional Committee of China Anti-Cancer Association;Integrated Gynecological Oncology Committee of China Anti-Cancer Association
出处 《癌症进展》 2025年第1期1-8,16,共9页 Oncology Progress
基金 辽宁省应用基础研究计划项目(2022JH2/101300039) 2022年沈阳市科技计划项目(22-321-33-08) 沈阳市科技局2023年助力中国医科大学高质量发展专项(23-506-3-01-10)。
关键词 妇科恶性肿瘤 骨转移 诊断 治疗 专家共识 gynecological malignant tumor bone metastasis diagnosis treatment expert consensus
  • 相关文献

参考文献11

二级参考文献87

  • 1李东晓,邓文龙.冰片促透作用研究进展[J].中药药理与临床,2007,23(1):87-88. 被引量:78
  • 2Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev, 2001, 27:165-176.
  • 3Johnson JR, Williams G, Pazdur R, et al. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol, 2003, 21 : 1404-1411.
  • 4Kinnane N. Burden of bone disease. Eur J Oncol Nuts, 2007, 11 Suppl 2 : S28-31.
  • 5Eubank WB, Mankoff DA. Evolving role of positron emission tomography in breast cancer imaging. Semin Nucl Med, 2005, 35:84-99.
  • 6Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol, 2007, 25: 1423-1436.
  • 7Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oneology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oneol, 2003, 21:4042-4057.
  • 8Weitnnan R, Sauter N, Eriksen EF, et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006. Crit Rev Oncol Hematol, 2007, 62:148-152.
  • 9Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J CIin Oncol, 2005, 23:4925-4935.
  • 10Brown JE, Thomson CS, Ellis SP, et al. Bone resorption predicts for skeletal complications in metastatic bone disease. Br J Cancer, 2003, 89:2031-2037.

共引文献511

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部